0000000000704742
AUTHOR
G. Guarneri
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma
We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …
Haemorragic syndrome in cattle by subgenotype BVDV-1h
Bovine viral diarrhoeaemucosal disease (BVD-MD) is caused by a Pestivirus. Two genotypes are recognized: BVDV-1 and BVDV-2. BVDV-1 causes diarrhoea, respiratory disorders and reproductive disorders. BVDV-2 causes a haemorrhagic syndrome. We describe several hypervirulent outbreaks characterized by severe haemorrhagic signs caused by BVDV-1 in Sicily.